Annovis Bio's Buntanetap Shows Promise in Reversing Cognitive Decline in Parkinson's Patients With Amyloid Co-Pathology

Annovis Bio Inc. (NYSE: ANVS) released new findings from its Phase 3 early Parkinson's disease study demonstrating that buntanetap halted cognitive decline across all patients and delivered the strongest benefit in those with mild dementia and amyloid co-pathology. This subgroup represents approximately 25% of the study population and typically experiences faster cognitive deterioration, but treatment with buntanetap reversed this decline and produced measurable reductions in pTau217, total tau and brain-derived tau—biomarkers associated with Alzheimer's pathology.

The company noted that the data reinforce its view that neurodegenerative diseases often overlap and require therapies capable of targeting multiple toxic proteins, positioning buntanetap as a potentially broad-acting treatment for cognitive impairment across Parkinson's and Alzheimer's disease biology. These findings are significant because they suggest a single therapy could address multiple aspects of neurodegeneration rather than targeting individual disease pathways separately.

For more detailed information about the study results, visit https://ibn.fm/CK0zo. Additional company information and updates are available at https://www.annovisbio.com and through the company's newsroom at https://ibn.fm/ANVS.

The implications of these findings extend beyond Parkinson's disease treatment, potentially offering new approaches for managing cognitive decline across multiple neurodegenerative conditions. The ability to reverse cognitive deterioration in patients with amyloid co-pathology represents a significant advancement, as this patient population has historically shown more rapid progression and poorer outcomes. The reduction in tau biomarkers further supports the mechanism of action targeting multiple toxic proteins simultaneously.